Human Longevity Extends $1M Cancer Pledge to Breast Cancer
San Francisco – October 16, 2026 -- Human Longevity, Inc. (HLI) now offers up to $1 million in treatment and clinical support to eligible members diagnosed with stage IV breast cancer, after expanding its Cancer Prevention Pledge to cover the disease. The support is subject to program terms.
CEO and Chairman Dr. Wei-Wu He says the company is confident enough in its detection approach that no member under its ongoing care should reach stage IV without earlier detection. The pledge is meant to provide backing if advanced cancer develops anyway.
Whole genome sequencing anchors the screening approach
HLI combines genome sequencing, advanced diagnostics, and ongoing physician care. Its program includes three elements: